USPTO Art Unit 3991 Prosecution Statistics

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17251961NIR-II EMISSIVE LUMINOGENSDecember 2020March 2024Allow3910YesNo
17115326LEVELS OF BCMA PROTEIN EXPRESSION ON B CELLS AND USE IN DIAGNOSTIC METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUSDecember 2020October 2023Abandon3420NoNo
17104166COMPOSITIONS AND METHODS FOR CHEMICAL SYNTHESISNovember 2020February 2024Allow3911YesNo
17001857METHODS FOR DETECTING CCR2 RECEPTORSAugust 2020February 2024Allow4131YesNo
16999818STRONGLY LEWIS ACIDIC METAL-ORGANIC FRAMEWORKS FOR CONTINUOUS FLOW CATALYSISAugust 2020March 2024Allow4321NoNo
16896742POLYCYCLOCARBONATE COMPOUNDS AND POLYMERS AND COMPOSITIONS FORMED THEREFROMJune 2020April 2024Allow4610NoNo
16761602FLUORESCENT PROBES FOR SILVER ION DETECTIONMay 2020March 2024Allow4731YesNo
16855957COMPOSITIONS AND METHODS OF USE FOR ALPHA-1 ANTITRYPSIN HAVING NO SIGNIFICANT SERINE PROTEASE INHIBITOR ACTIVITYApril 2020May 2022Abandon2510NoNo
16755359EPIDERMAL PENETRATION TYPE INK COMPOSITIONApril 2020May 2024Allow4931NoNo
16781025PROCESSES FOR THE PRODUCTION OF FLUOROPROPANES AND HALOPROPENESFebruary 2020September 2022Abandon3210NoNo
16609136Peptide-Containing Adjuvant Compounds Having PEG SpacersOctober 2019February 2024Allow5221YesNo
16573570COMPOSITIONS AND METHODS FOR IMAGING CELLSSeptember 2019April 2024Allow5561NoNo
16265386SOLID-SUPPORTED CATALYST FOR CROSS-COUPLINGFebruary 2019June 2019Allow410NoNo
16265425ARYL HALIDE CROSS-COUPLING METHOD AND PRODUCT MADE THEREFROMFebruary 2019June 2019Allow410NoNo
16210163[4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOFDecember 2018May 2019Allow510NoNo
16210066PROCESS FOR PREPARING CYCLOPHOSPHAMIDE, INTERMEDIATES, AND MONOHYDRATE THEREOFDecember 2018September 2019Allow1000NoNo
16179785PRE-TARGETING STRATEGIES FOR MOLECULAR IMAGING AND/OR RADIOIMMUNOTHERAPYNovember 2018February 2024Allow6061YesNo
16093508METHODS OF TREATING BREAST CANCEROctober 2018March 2024Allow6071YesNo
16078396TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOFAugust 2018August 2019Allow1200NoNo
16076797SUBSTITUTED IMIDAZOLYLCARBOXAMIDES AS PESTICIDESAugust 2018July 2019Allow1100NoNo
16054713BIOFILM INHIBITING COMPOSITIONS ENHANCING WEIGHT GAIN IN LIVESTOCKAugust 2018March 2019Allow810NoNo
16029455ELECTRIC WIRE FOR HIGH FREQUENCY, HIGH VOLTAGE AND LARGE CURRENTJuly 2018November 2020Allow2820NoNo
15922376BETA-LACTAMASE INHIBITORSMarch 2018January 2019Allow1010NoNo
15759600MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASEMarch 2018July 2019Allow1610NoNo
15915415Boron-Containing Diacylhydrazine CompoundsMarch 2018October 2019Allow1911NoNo
15748557CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORSJanuary 2018October 2019Allow2011NoNo
15864650GOLD(I) COMPLEXES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATING PROLIFERATIVE DISORDERSJanuary 2018November 2018Allow1110NoNo
15831357XYLANASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEMDecember 2017February 2020Abandon2710NoNo
15801781NOVEL CRYSTALLINE FORMSNovember 2017August 2019Allow2120NoNo
15792777VOLTAGE CONVERSION MODULE AND BOBBINOctober 2017July 2020Allow3320YesNo
15709031LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICESeptember 2017January 2020Abandon2820NoNo
15706785POWER CONVERSION SYSTEMSeptember 2017January 2021Allow4030YesYes
15558106METHOD FOR CALIBRATING A POLARISATION AXIS MEASURING DEVICE AND METHOD FOR DETERMINING POLARISATION AXES OF SPECTACLE LENSES FOR A POLARISATION AXIS MEASURING DEVICESeptember 2017August 2018Allow1110YesNo
15532298LUMINESCENT PALLADIUM(0) AND PLATINUM(0) CARBENE COMPLEXES FOR OLEDSJune 2017June 2018Allow1200NoNo
15488762SELF-ASSEMBLY OF NANOSTRUCTURESApril 2017November 2019Allow3141NoNo
15459693Zinc or Copper (II) Salt and Use Thereof as a BiocideMarch 2017December 2017Allow920NoNo
15452839METATHESIS CATALYSTMarch 2017September 2017Allow710NoNo
15362997SOLID-SUPPORTED PALLADIUM (II) COMPLEX AS A HETEROGENEOUS CATALYST FOR CROSS COUPLING REACTIONS AND METHODS THEREOFNovember 2016January 2019Allow2610NoNo
15314256Bi-Nuclear Main Group Metal Phosphorescent EmitterNovember 2016August 2019Allow3221NoNo
15353453PROTECTIVE LAYERS PRODUCED BY SOL GEL PROCESSESNovember 2016August 2019Allow3312NoNo
15353256COLOR CONVERSION FILMS PRODUCED BY UV CURING PROCESSESNovember 2016August 2019Allow3312NoNo
15353509PROTECTIVE LAYERS PRODUCED BY UV CURING PROCESSESNovember 2016August 2019Allow3312NoNo
15353373RED ENHANCEMENT IN WHITE LED DISPLAYS USING UV-CURED COLOR CONVERSION FILMSNovember 2016August 2019Allow3312NoNo
15332793Variants of C-Type Natriuretic PeptideOctober 2016May 2018Abandon1810NoNo
15282636METHOD FOR TREATING PROSTATE CANCER AND/OR GASTROINTESTINAL CANCERSeptember 2016January 2017Allow400YesNo
15281735METHOD FOR TREATING A CANCER WITH A MIXED LIGAND GOLD(III) COMPLEXES AS ANTI-CANCER AGENTSSeptember 2016January 2017Allow310NoNo
15273582PROCESS FOR PREPARING IMIDAZOLIUM BASED IONIC LIQUIDS WITH DI-POLYMERIZED OXIRANE BASESeptember 2016February 2018Allow1710NoNo
15126422DESIGN, SYNTHESIS, AND BIOLOGICAL ACTIVITY OF PLATINUM-BENZ[C]ACRIDINE HYBRID AGENTS AND METHODS ASSOCIATED THEREWITHSeptember 2016October 2017Allow1300NoNo
15164002PHOSPHINE LIGANDS FOR CATALYTIC REACTIONSMay 2016January 2017Allow820NoNo
15092906PHOSPHORESCENT ORGANOMETALLIC IRIDIUM COMPLEX, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICEApril 2016July 2018Allow2711NoNo
15027008Method for Preparation of Cyano Compounds of the 13th Group with a Lewis AcidApril 2016June 2016Allow300NoNo
15081308PALLADIUM(II) COMPLEX FOR CATALYZING SONOGASHIRA COUPLING REACTIONS AND A METHOD THEREOFMarch 2016November 2016Allow810NoNo
14916547PHOTOLABILE LINKER FOR THE SOLID-PHASE SYNTHESIS OF HYDRAZIDES AND PYRANOPYRAZOLESMarch 2016August 2017Allow1710NoNo
15056580MOLECULAR SWITCHES BASED ON CIS/TRANS ISOMERIZATION OF BF2-COORDINATED AZO COMPOUNDSFebruary 2016October 2017Allow1910NoNo
14907147PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUNDJanuary 2016May 2018Allow2811NoNo
14902514PRECISE DELIVERY OF THERAPEUTIC AGENTS TO CELL MITOCHONDRIA FOR ANTI-CANCER THERAPYDecember 2015February 2018Allow2611NoNo
14898410METHOD FOR PRODUCING SALTS HAVING MONOFLUORO-TRICYANOBORATE ANIONSDecember 2015May 2016Allow500NoNo
14892451RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTSNovember 2015September 2017Allow2200NoNo
14941167METHOD FOR PRODUCING LINEAR PENTENENITRILENovember 2015July 2016Allow810NoNo
14855646BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDSSeptember 2015December 2017Allow2711NoNo
14850063MIXED LIGAND GOLD(III) COMPLEXES AS ANTI-CANCER AGENTSSeptember 2015August 2016Allow1100NoNo
14774570ORGANIC OLIGOMERS OF ACYLGLYCEROLSeptember 2015January 2018Allow2820NoNo
14834420PHOSPHINE LIGANDS FOR CATALYTIC REACTIONSAugust 2015February 2016Allow610NoNo
14798071MIXED LIGAND GOLD(III) COMPLEXES AND METHODS THEREOFJuly 2015July 2016Allow1200NoNo
14759778ORGANIC DYE FOR A DYE SENSITIZED SOLAR CELLJuly 2015August 2017Allow2621NoNo
14651239Process for Preparing Asymmetrical Imidazolium SaltsJuly 2015February 2017Allow2010NoNo
14758421DITHIENYLPYRROLE-BASED BIOSENSORS AND METHODS FOR THEIR PREPARATION AND USEJune 2015September 2017Allow2701NoNo
14441304DIHYDROTHIOPHENE DERIVATIVES AS INSECTICIDAL COMPOUNDSMay 2015August 2019Allow5151NoYes
14705527COPPER-CATALYSED LIGATION OF AZIDES AND ACETYLENESMay 2015December 2015Allow710NoNo
14705627N-HETEROCYCLIC CARBENE GOLD COMPLEXES WITH ANTICANCER PROPERTIES AND METHODS OF USE THEREOFMay 2015December 2016Allow2010NoNo
14669606ORGANIC LIGHT-EMITTING DEVICE AND METHOD OF PRODUCING THE SAMEMarch 2015March 2019Allow4840YesNo
14660488Variants of C-Type Natriuretic PeptideMarch 2015May 2018Abandon3810NoNo
14627544NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODIFIED PHENOTYPE CHARACTERISTICS IN PLANTSFebruary 2015April 2019Allow5001NoNo
14611943PHOSPHINE LIGANDS FOR CATALYTIC REACTIONSFebruary 2015April 2015Allow300NoNo
14610519METHODS FOR PREPARING RUTHENIUM CARBENE COMPLEX PRECURSORS AND RUTHENIUM CARBENE COMPLEXESJanuary 2015December 2016Allow2310NoNo
14417934BORON-CONTAINING 5-ARYLIDENE-3,5-DIHYDRO-4H-IMIDAZOL-4-ONESJanuary 2015July 2015Allow610NoNo
14591819STEM CELL CULTURE MEDIUM AND METHOD OF USING SAID MEDIUM AND THE CELLSJanuary 2015August 2016Allow1910YesNo
14412888Polysilylated Organosilane CompoundsJanuary 2015October 2017Allow3311NoNo
14581571SYNTHETIC LIGATION REASSEMBLY IN DIRECTED EVOLUTIONDecember 2014May 2018Abandon4010NoNo
14408863SILOXANE-BASED PIPE COATINGSDecember 2014March 2018Allow3931YesNo
14572015Soft Protease Inhibitors and Pro-Soft Forms ThereofDecember 2014July 2015Allow710NoNo
14546661PROCESS FOR THE PREPARATION OF PERFLUOROALKYLCYANO- OR PERFLUOROALKYLCYANOFLUOROBORATESNovember 2014August 2015Allow910NoNo
14521317XYLANASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEMOctober 2014July 2019Abandon5720NoNo
14507453BORON-CONTAINING SMALL MOLECULESOctober 2014May 2015Allow810NoNo
14387890COMPOSITIONS AND METHODS RELATED TO INHIBITORS OF JAK KINASESeptember 2014February 2016Allow1710NoNo
14121568SYNTHESIS AND STRUCTURE OF 3,5-DIAMINO-2,6-DI-(TERT-BUTYI-NNO-AZOXY) PYRAZINE AS A CRITICAL INTERMEDIATE IN THE SYNTHESIS OF A NOVEL ENERGETIC COMPOUNDSeptember 2014January 2017Allow2810NoNo
14484435FIBER REINFORCED THERMOPLASTIC SHEETS WITH SURFACE COVERINGSSeptember 2014November 2016Abandon2610NoNo
14461082ANTIBODIES TO TROPONIN I AND METHODS OF USE THEREOFSeptember 2014April 2018Abandon4420NoNo
14478581METHODS FOR PRODUCING BORYLATED ARENESSeptember 2014June 2018Allow4522YesNo
14470362IMAGE TRANSFER SHEETAugust 2014June 2016Allow2230YesYes
14467625PHOSPHINE LIGANDS FOR CATALYTIC REACTIONSAugust 2014September 2015Allow1320NoNo
14267455METHODS FOR PREPARING RUTHENIUM CARBENE COMPLEX PRECURSORS AND RUTHENIUM CARBENE COMPLEXESMay 2014January 2017Allow3211NoNo
14353511SILYLATED AZULENYL NITRONE SPIN TRAPS AS CHROMOTROPIC SUPEROXIDE DETECTORSApril 2014May 2015Allow1300NoNo
14348407RUTHENIUM POLYMERISATION CATALYSTSMarch 2014July 2017Allow3921YesNo
14226884AZO MEDIATORS AND METHODS OF USE THEREOFMarch 2014August 2017Allow4022NoNo
14343235METAL NICKEL-IMIDAZOLATE CHIRAL NANO CLATHRATE COMPLEX AND PREPARATION METHOD THEREOFMarch 2014February 2015Allow1210NoNo
14176571METHOD FOR PURIFYING A CRUDE PNPNH COMPOUNDFebruary 2014September 2015Allow1910NoNo
14174669COMPOSITIONS AND METHODS FOR CYTOPROTECTIONFebruary 2014August 2014Allow610NoNo
14000116Process to Obtain a Trifluoromethylating CompositionJanuary 2014February 2017Allow4231NoNo
14232673COMPOUNDS CONTAINING ALKYL-ALKOXY-CYANO-BORATE ANIONSJanuary 2014May 2014Allow400NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 3991.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
2
Examiner Affirmed
0
(0.0%)
Examiner Reversed
2
(100.0%)
Reversal Percentile
100.0%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
31
Allowed After Appeal Filing
14
(45.2%)
Not Allowed After Appeal Filing
17
(54.8%)
Filing Benefit Percentile
92.7%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 45.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 3991 - Prosecution Statistics Summary

Executive Summary

Art Unit 3991 is part of Group 3990 in Technology Center 3900. This art unit has examined 483 patent applications in our dataset, with an overall allowance rate of 96.3%. Applications typically reach final disposition in approximately 32 months.

Comparative Analysis

Art Unit 3991's allowance rate of 96.3% places it in the 95% percentile among all USPTO art units. This art unit has a significantly higher allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 3991 receive an average of 1.65 office actions before reaching final disposition (in the 31% percentile). The median prosecution time is 32 months (in the 44% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.